G1‐S transition defects occur in most breast cancers and predict outcome Niels Hilmer NielsenMartin LodénGöran Landberg OriginalPaper Pages: 103 - 110
Postoperative chemo–endocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor–positive stage II breast cancer Keizo SugimachiYoshihiko MaeharaYasumasa Monden OriginalPaper Pages: 111 - 122
Three new active cisplatin‐containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial Giorgio CocconiGiancarlo BisagniLuisa Savoldi OriginalPaper Pages: 123 - 130
Meta‐analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer S. PyrhönenJ. EllménD.F. Hayes OriginalPaper Pages: 131 - 141
Expression of inducible nitric oxide synthase in human breast cancer depends on tumor grade Walter TschugguelChristian SchneebergerJohannes C. Huber OriginalPaper Pages: 143 - 149
Overexpression of basic fibroblast growth factor (FGF–2) downregulates Bcl–2 and promotes apoptosis in MCF–7 human breast cancer cells Paul MaloofQin WangRobert Wieder OriginalPaper Pages: 151 - 165
Immunohistochemical labelling for prostate–specific antigen in breast carcinomas Kalle A. AlanenTeijo KuopioTimo J. Nevalainen OriginalPaper Pages: 167 - 174
PACAP (6–38) is a PACAP receptor antagonist for breast cancer cells Julius LeytonYehoshua GozesTerry W. Moody OriginalPaper Pages: 175 - 184
Hsp27 overexpression inhibits doxorubicin–induced apoptosis in human breast cancer cells Rhonda K. HansenIrma ParraSuzanne A. W. Fuqua OriginalPaper Pages: 185 - 194